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Objectives: Most national standard therapeutic guidelines recommend a 52-week 
trastuzumab regimen for breast cancer treatment. In contrast, the Iranian national 
guideline (published by the Ministry of Health) recommends a nine-week regimen. We 
assessed the differences between current routine practice amongst Iranian specialists 
and the guidelines for trastuzumab treatment and HER2 receptor testing in breast 
cancer. MethOds: 128 Iranian hematology oncologists and radiotherapy oncologists 
were asked to complete an online anonymous questionnaire. Concurrently, a 3-year 
retrospective claims database analysis was conducted using data from the Social 
Security Organization, a health insurer which covers approximately 50% of the Iranian 
population, to enable comparisons with the questionnaire results. Results: With 
a 41% (52/128) response rate, doctors reported a relatively high absolute adherence 
(86%) to the guideline for HER2 receptor testing but a low rate of absolute adherence 
(6%) to the guideline for duration of trastuzumab treatment. Doctors indicated that 
the planned duration was 9 weeks in only 32% of patients; in most cases, the plan 
was 52-week treatment. Patients with a 9-week treatment plan received trastuzumab 
for 8.6 weeks on average while patients with 52-week plans received treatment for 
29.2 weeks. The general trends found in the survey were confirmed in the claims 
database analysis of 830 HER2 positive patients. cOnclusiOns: When it comes to 
trastuzumab use, Iranian doctors appear to rely more on the medical literature than 
on national guidelines developed by the Ministry of Health. Policymakers, doctors 
and the general public should try to reach some consensus about the optimal way to 
treat eligible patients. This is particularly necessary in low-middle income countries, 
whose limited budget cannot easily accommodate all of the innovative technologies 
to come. Inventive reimbursement policies may form part of the solution as long as 
the experiences from other countries are examined.
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Objectives: Trastuzumab (TRA) subcutaneous (SC) injection is an alternative to 
intravenous (IV) administration for the treatment of HER2+ early breast cancer (EBC). 
The objective was to quantify health care professional (HCP) time and patient chair 
time related to TRA treatment to estimate potential time and cost savings with a 
transition from IV to SC. MethOds: A multi-centre, prospective time-and-motion 
study was run in three Russian centres participating in the SafeHer clinical trial 
(MO28048). Case report forms listing pre-specified tasks for IV, SC, and pharmacy 
management in chronological order and tailored to site practices were used for data 
collection. Trained observers recorded patient chair time and durations that HCPs 
were actively completing the tasks. A random effects regression model was run for 
each task to generate mean and 95% confidence intervals. IV vs. SC process time was 
calculated as the sum of the mean task times. HCP and chair time were translated to 
cost using Russian salary data, and 354 roubles (p) per infusion chair hour. Results: 
Mean reduction in HCP time per patient session was 18.6min (-48%) (IV: 38.7min vs. 
SC: 20.1min; centre range: 8.6-31.1min), of which 61% of time reduced was achieved 
in the treatment room. Per treatment session (total 18 sessions), the estimated time 
saving was 5.6 hours (range across centres: 2.6-9.3hours). Reduction in mean chair 
time was 59.5min (-89%) (IV: 67.1min vs. SC: 7.6min; centre range: 29.8-97.3min). 
The monetary value of HCP and patient chair time saved was 1,175p and 6,314p, 
respectively, for 18 treatment sessions. cOnclusiOns: Transition from IV to SC TRA 
leads to substantial reductions in administration chair time, active HCP time and 
associated costs. This allows more time to be used for other patient care activities, 
increasing the number of patients who could be treated and thus increasing the 
overall efficiency of treatment centers.
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Objectives: The present study aimed to examine how breast cancer patients 
proceed through the public Greek health care system by using process mapping to 
identify constraints and bottlenecks and unnecessary process steps. MethOds: 
The sample of the study were 86 patients diagnosed with breast cancer at two 
large public oncological hospitals. A process mapping study, by applying PERT 
(Program Evaluation Review Technique) analysis, was conducted. Results: The 
total time spent for obtaining the treatment (per os or chemotherapy) is higher up 
to 7 times compared with the time spent in activities contributing directly towards 
the patient’s outcome. The average time needed to complete the procedure (e.g. 
physician consultation, waiting times, prescribing, obtaining pharmaceuticals) 
in Hospital A was 78.65 minutes (SD= 37.43) while waiting time was 51 minutes 
(64.9%). In Hospital B the respective time was 101 min (SD= 50.54) and 83.1% of that 
time was the waiting time. Similarly, the average time required for chemotherapy 
at Hospital A was 4 hours and 27 minutes (SD= 106.61) while the waiting time was 
2 hours and 15 minutes (50.8%). In Hospital B, the average time for chemotherapy 
was 3 hours 35 minutes (SD= 69.49) and 52.2% of that time was the waiting time. 
Among the main reasons for the delays were the lack of electronic records and 
poor function of the Central Information Prescribing System. cOnclusiOns: 
Waiting time represented the higher percentage of the total time needed to com-
plete the process for obtaining the treatment. As it represents one of the major 
causes for patient dissatisfaction, applying process mapping is a critical step for 
health care organizations to improve the beneficial time and the overall quality 
of the services offered.
0.2% (pancreas cancer) to 16.6% leukemia for females. Inconsistent changes were 
noticed for either incidence or mortality of different cancers. There were no sta-
tistically significant correlations between change in 5-year survival, and change 
in incidence and mortality for either male or female cancers during this period. 
When other time periods were considered for analysis, statistically significant 
correlations were noticed between change in 5-year survival and incidence of 
male cancers from 1981 to 1995 (Pearson r= 0.68; P= 0.03) and from 1986 to 1995 
(Pearson r= 0.78; P= 0.007). However, when the two mostly overdiagnosed cancers 
(prostate and breast) were excluded, there were no correlations between change 
in 5-year survival, and change in incidence and mortality for the three time peri-
ods. cOnclusiOns: Our study shows no reliable relationships between changes 
in 5-year survival and incidence or mortality. The increase in 5-year survival might 
not represent progress in cancer control, but instead indicate improved diagnosis 
and treatment in clinical practice.
PCN218
aSSeSSmeNT of luNg CaNCer TreaTmeNT by diSeaSe PhaSe uSiNg 
NaTioNal CaNCer regiSTry daTa liNked WiTh TreaTmeNT PaThWay 
CoST daTa iN auSTria
Zauner G.1, Popper N.1, Breitenecker F.2
1dwh GmbH, Vienna, Austria, 2Vienna University of Technology, Vienna, Austria
Objectives: Pilot study for evaluation of record linking and potential analysis of 
combination of epidemiologic cancer registry data and personalized pathway of 
care identified by billing data using lung cancer as test illness for Austrian data-
sets in the years 2006 till 2011. MethOds: Data sets are linked by anonymized 
distinct social insurance numbers of approximately 85 percent of all detected 
incident lung cancer patients in Austria in the years 2006 till 2011 with billing 
data on single person level. The calculated dataset deals as starting point for the 
analysis of the remaining lifetime distribution depending on age and TNM – state. 
Analysis of care classified by eight main categories given in hospitals coded by the 
MEL-system in combination with treatment using defined drugs is analysed and 
reported for further interpretation by the experts. An exploratory data analysis on 
the socio-economic standard and regional differences in Austrian federal states 
complete the pilot study. Results: Data for the whole Austrian health insured 
population, including incident cases for lung cancer over a time span of two years 
were analysed for the following chronic diseases detected by predefined rules 
on hospital diagnoses and drug prescription in the one year preceding patient 
history: COPD, diabetes and psychiatric illnesses. For the detected 6616 patients 
the probability of surviving is calculated and visualized by Kaplan-Meier-Curves. 
Exemplarily the one year survival is given: 75,44% and the 3-years life expectancy: 
~1% Further results combining different influence factors on survival including 
data from the cancer registry information table are performed. cOnclusiOns: 
Combining data collected by the national epidemiological cancer registry system 
and personalized pathways of patient treatment in intramural and extramural care 
provides a broad basis for analysis concerning real world pathway comparison 
of cancer patients. This work can unlock potential in respect of defining clinical 
national cancer registries.
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Objectives: Clinical oncology societies develop and regularly update evidence-
based guidelines in order to achieve more reliable and updated tools for patient 
management. In 2004 AIOM (Italian Association of Medical Oncology) created the 
RIGHT program: Research for the Identification of the most effective and hIGHly 
accepted clinical guidelines for cancer Treatment. It aims to evaluate the concord-
ance between AIOM breast (BC), colorectal (CRC) and lung (LC) cancer guidelines 
and clinical practice in Italian cancer centers. MethOds: the RIGHT program is 
composed by three retrospective observational studies, one for each guideline, 
conducted in a sample of 35 (BC) +37 (CRC) +53 (LC) Italian centers for cancer 
care representative of 230 AIOM centers. Site sampling from AIOM database was 
stratified by geographic distribution (North, Center, South). Indicators were iden-
tified to verify the concordance between AIOM guidelines and clinical practice 
about staging and treatment. Patients were included if they had their first visit 
at the site after guideline emission. Patients were then followed-up for at least 
6 months. Results: Patients enrolled for the breast, colorectal and lung cancer 
guideline evaluation were 324, 326, and 708, respectively. Adherence was on aver-
age 69% for BC, 76% for CRC and 69% for LC. For CRC adherence was 78% for colon, 
69% for rectal cancer and 83% for advanced disease. For BC, the lowest degree 
of compliance (0%) was observed for the follow-up indicator in asymptomatic 
patients. For LC, on average 67%, 46% and 81% of stage I-II-IIIA, IIIB and IV patients 
respectively received recommended care according to defined lung cancer indi-
cators cOnclusiOns: The RIGHT program showed that guidelines adherence 
is generally high, with very few cases of low adhererence. Guidelines adherence 
monitoring and update represent crucial activity to get more useful instrument 
to plan health care interventions.
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